Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT06676826
Recruiting Not applicable

Treatment of Periodontal Intra-bony Defects With a Volume Stable Collagen Matrix or Deproteinized Bovine Bone Mineral With 10% Collagen

NCT06676826 · tracked via the Priya Life Science Switzerland tracker
Sponsor
University of Bern
Phase
Not applicable
Started
2025-09-01
Last updated
2025-10-06

Condition(s) studied

Periodontal Diseases

Investigational drug(s) / intervention(s)

Infrabony defects will be filled with a volume-stable collagen matrix (VCMX)Infrabony defects will be filled treated with a deproteinized bovine bone mineral with 10% collagen

Infrabony defects will be filled with a volume-stable collagen matrix (VCMX): Infrabony defects will be filled with a volume-stable collagen matrix

Infrabony defects will be filled treated with a deproteinized bovine bone mineral with 10% collagen: Infrabony defects will be filled with with a deproteinized bovine bone mineral with 10% collagen

Study summary

To compare the healing of intrabony periodontal defects treated with either open flap debridement and a volume-stable collagen matrix (VCMX) or a deproteinized bovine bone mineral with 10% collagen. The results will shed light on the clinical potential of VCMX in regenerative periodontal surgery and help to develop new treatment strategies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria * Patients with localized or generalized periodontitis Stage III and Stage IV, Grade A-B-C * Males and females * Age at least 18 years and older * Presence of interdental intra-bony defects (I, II and III walls) in either the maxilla or the mandible with a PD ≥ 6 mm * Defects with an intra-bony component \> 3 mm for both groups * Intra-bony defect located only at one aspect (mesial or distal) * Presence of at least 2 mm of keratinized soft tissue. Exclusion Criteria * Patients with systemic disease that could interfere with periodontal wound healing * Prolonged antibiotic treatment or anti-inflammatory treatment within 4 weeks prior to surgery * Pregnant or lactating * Smokers with \> 10 cig./day * Patients with FMPS and FMBS \> 25 % after completion of non-surgical periodontal therapy * Multi-rooted teeth with furcation involvement * Third molars * Teeth with circumferential defects * Interdental craters * Written Informed Consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Bern Bern Switzerland Recruiting

More University of Bern trials in Switzerland

Titanium Zirconium (TiZr) Mini Implants Active, not recruiting
Cardiac Dysfunction in Childhood Cancer Survivors Recruiting
A Swiss Interprofessional Network for Reviewing Inappropriate Medication in Primary Care Enrolling by invitation
The Development of MASLD Among Survivors of Breast or Colorectal Cancer Recruiting
Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 7 of 7) Active, not recruiting

Other trials for the same condition

Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06676826 on ClinicalTrials.gov ↗ ← All trials in Switzerland